| Literature DB >> 35661341 |
Raffaele Pagliuca1, Maria Grazia Cupido2, Giacomo Mantovani2, Maura Bugada2, Giulia Matteucci2, Arturo Caffarelli2, Federico Bellotti2, Raffaella Cocchieri2, Antonio Dentale2, Federica Lozzi2, Paola Malagoli2, Pasquale Morabito2, Gianluca Serra2, Candida Andreati2.
Abstract
METHODS: A limited amount of data is now available on prognostic factors and mortality among elderly people resident in Long-Term Care facilities and in post-acute units. These populations (in particular those with underlying chronic medical conditions) seem to have higher risk of morbidity and mortality related to COVID-19 disease, but further evidence is needed. The aim of our study is to investigate the impact of some well-known prognostic factors in elderly patients (≥ 65 years) with COVID-19 admitted in the Long-Term Care setting in AUSL Ferrara, Italy. We performed binary regression logistic analysis for some variables (demographic data, clinical data including nasal swab test (NST) at discharge and frailty assessments) to find potential predictors of mortality. We subsequently tested statistically significant variables using Kaplan-Meier curves and Cox-regression models to find survival outcomes and related hazard ratio.Entities:
Keywords: COVID-19; Long-Term Care Frailty COVID; Nasal swab test
Mesh:
Year: 2022 PMID: 35661341 PMCID: PMC9166148 DOI: 10.1007/s41999-022-00657-x
Source DB: PubMed Journal: Eur Geriatr Med ISSN: 1878-7649 Impact factor: 3.269
Descriptive analysis and difference between patients discharged alive or dead
| Survived | Dead | Tot | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Avg | 330 | % | Avg | 132 | % | Avg | 452 | |||
| Age | 82.07 | 86.52 | 83.30 | |||||||
| Charlson comorbidity index | 5.11 | 4.80 | 5.02 | 0.21 | ||||||
| CFS | 4.66 | 6.36 | 5.12 | |||||||
| Number of drugs | 5.89 | 5.88 | 5.88 | 0.96 | ||||||
| Days of hospitalization | 22.98 | 22.65 | 22.89 | 0.83 | ||||||
| Sex | Female | 183 | 55.5 | 89 | 73.0 | 272 | ||||
| NST at discharge | Positive | 117 | 35.5 | 96 | 78.7 | 213 | ||||
| Setting of origin | Others than home | 72 | 21.8 | 57 | 46.7 | 129 | ||||
| ADL < 2 | 103 | 31.2 | 84 | 68.9 | 187 | |||||
| Venous catheter | 43 | 13.0 | 22 | 18.0 | 65 | 0.17 | ||||
| Enteral nutrition | 3 | 9 | 0 | 0.0 | 3 | 0.29 | ||||
| Urinary catheter | 84 | 25.5 | 36 | 29.5 | 120 | 0.75 | ||||
| Hypertension | 245 | 74.2 | 82 | 67.2 | 327 | 0.13 | ||||
| Rheumatic disease | 25 | 7.6 | 9 | 7.4 | 34 | 0.94 | ||||
| Diabetes | 79 | 23.9 | 31 | 25.4 | 110 | 0.74 | ||||
| Cardiovascular disease | 162 | 49.1 | 76 | 62.3 | 238 | |||||
| Vasculopathy | 142 | 43.0 | 49 | 40.2 | 191 | 0.58 | ||||
| Cerebrovascular disease | 71 | 21.5 | 36 | 29.5 | 107 | 0.076 | ||||
| Respiratory disease | 53 | 16.1 | 16 | 13.1 | 69 | 0.44 | ||||
| Liver disease | 21 | 6.4 | 5 | 4.1 | 26 | 0.35 | ||||
| Kidney disease | 59 | 17.9 | 22 | 18.0 | 81 | 0.97 | ||||
| Musculoskeletal disease | 121 | 36.7 | 58 | 47.5 | 179 | 0.036 | ||||
| Cancer | 88 | 26.7 | 28 | 23.0 | 116 | 0.42 | ||||
| Hematological disease | 44 | 13.3 | 16 | 13.1 | 60 | 0.952 | ||||
| Dementia | 150 | 45.5 | 82 | 67.2 | 232 | |||||
| Endocrinopathy | 40 | 12.1 | 16 | 13.1 | 56 | 0.776 | ||||
| Obesity | 52 | 15.8 | 11 | 9.0 | 63 | 0.66 | ||||
| Infection | 83 | 25.2 | 72 | 59.0 | 155 | |||||
The significante of bold values is referred to the statistical significance of a result (p < 0,05)
CFS clinical frailty scale, ADL activity of daily living, NST nasal swab test
Comparison between 2 years, same hospital ward
| February 2019–February 2020 | March 2020–March 2021 | ||||||
|---|---|---|---|---|---|---|---|
| Avg | % | Avg | % | ||||
| Over 65 | 519 | 452 | |||||
| Sex female | 325 | 62.6 | 272 | 60.17 | 0.6 | ||
| Days of hospitalization | 21.7 | 22.89 | |||||
| Number of drugs | 5.92 | 5.88 | 0.78 | ||||
| Charlson | 4.95 | 5.02 | |||||
| CFS | 5.22 | 5.12 | |||||
| ADL < 2 | 274 | 52.8 | 253 | 56.0 | 0.58 | ||
| Setting of origin (other than home) | 211 | 40.7 | 129 | 28.5 | |||
| Death | 126 | 24.3 | 122 | 26.9 | 0.33 | ||
| Male | 57 | 11.0 | 33 | 7.3 | 0.1 | ||
| Female | 69 | 13.3 | 89 | 19.6 | |||
The significante of bold values is referred to the statistical significance of a result (p < 0,05)
Predictors of mortality in COVID-19-positive patients by binary logistic regression model
| Sig | Exp(B) | 95% CI Inf | 95% CI Sup | |
|---|---|---|---|---|
| Age | 1.062 | 1.021 | 1.104 | |
| CFS | 1.519 | 1.214 | 1.899 | |
| Sex | .659 | .371 | 1.172 | |
| NST at discharge | 6.662 | 3.751 | 11.834 | |
| Setting of origin | .331 | 1.378 | .722 | 2.627 |
| ADL < 2 | .204 | 1.578 | .780 | 3.192 |
| Cardiovascular disease | .108 | 1.566 | .906 | 2.707 |
| Musculoskeletal disease | .079 | 1.634 | .945 | 2.825 |
| Dementia | .138 | .606 | .313 | 1.175 |
| Infection | 2.332 | 1.351 | 4.026 | |
| Constant | .000 | .000 |
The significante of bold values is referred to the statistical significance of a result (p < 0,05)
CFS clinical frailty scale, ADL activity of daily living, NST nasal swab test
Fig. 1Survival with CFS ≥ 5 (green) or < 5 (blue)
Fig. 2Survival with positive (green) or negative (blue) nasal swab test at discharge
Cox-regression model between overall survival and age, CFS, NST and infection
| Sig | Exp(B) | 95% CI Inf | 95% CI Sup | |
|---|---|---|---|---|
| Age | 1.058 | 1.029 | 1.088 | |
| CFS | 1.320 | 1.164 | 1.496 | |
| NST at discharge | 6.646 | 4.091 | 10.795 | |
| Infection | .481 | 1.149 | .782 | 1.688 |
The significante of bold values is referred to the statistical significance of a result (p < 0,05)
CFS clinical frailty scale; NST nasal swab test
Predictors of nasopharyngeal swab at discharge in COVID-19-positive patients by binary logistic regression model
| Sig | Exp(B) | 95% CI Inf | 95% CI Sup | |
|---|---|---|---|---|
| CFS | 1.191 | 1.068 | 1.327 | |
| Age | .594 | 1.007 | .981 | 1.035 |
The significante of bold values is referred to the statistical significance of a result (p < 0,05)
CFS clinical frailty scale